PRESCRIBING INFORMATION

3.3% Dextrose and 0.3% Sodium Chloride Injection

5% Dextrose and 0.2% Sodium Chloride Injection

5% Dextrose and 0.45% Sodium Chloride Injection

5% Dextrose and 0.9% Sodium Chloride Injection

10% Dextrose and 0.9% Sodium Chloride Injection

Dextrose and Sodium Chloride Injection, USP

Solution for infusion

Intravenous Fluid and Nutrient Replenisher

In VIAFLEX Plastic Container

Baxter Corporation
Mississauga, Ontario L5N 0C2
Canada

Date of Revision:
December 14, 2018

Submission Control No: 221959

Baxter and VIAFLEX are Trademarks of Baxter International Inc.
Dextrose and Sodium Chloride Injection, USP
In VIAFLEX Plastic Container

SUMMARY PRODUCT INFORMATION

Dextrose and Sodium Chloride Injection USP solutions are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents or added buffers. The composition, osmolarity and approximate pH of the individual solutions are shown in Table 1.

<table>
<thead>
<tr>
<th>Size (mL)</th>
<th>DIN</th>
<th>Composition (g/L)</th>
<th>Osmolarity (mOsmol/L)</th>
<th>pH</th>
<th>Ionic Concentration (mmol/L)</th>
<th>Caloric Content (cal/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Dextrose Monohyd.</td>
<td>Sodium Chloride</td>
<td></td>
<td>Sodium</td>
<td>Chloride</td>
</tr>
<tr>
<td>3.3% Dextrose &amp; 0.3% NaCl</td>
<td>500</td>
<td>00060712</td>
<td>33.0 g</td>
<td>3.0 g</td>
<td>271</td>
<td>3.5 to 6.5</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5% Dextrose &amp; 0.2% NaCl</td>
<td>500</td>
<td>00060704</td>
<td>50.0 g</td>
<td>2.0 g</td>
<td>321</td>
<td>3.5 to 6.5</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5% Dextrose &amp; 0.45% NaCl</td>
<td>500</td>
<td>00060739</td>
<td>50.0 g</td>
<td>4.5 g</td>
<td>406</td>
<td>3.5 to 6.5</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5% Dextrose &amp; 0.9% NaCl</td>
<td>500</td>
<td>00060747</td>
<td>50.0 g</td>
<td>9.0 g</td>
<td>560</td>
<td>3.5 to 6.5</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10% Dextrose &amp; 0.9% NaCl</td>
<td>1000</td>
<td>00060755</td>
<td>100.0 g</td>
<td>9.0 g</td>
<td>813</td>
<td>3.5 to 6.5</td>
</tr>
</tbody>
</table>

*The dextrose is purified from corn and may contain fructose.

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic).

Water in a solution in the container can permeate through the plastic wall, but in an insufficient amount to significantly affect the solution. Before the product expires, very small amounts of chemical components of the plastic can be leached into the solution in the container, such as up to 5 parts per million for di-2-ethylhexyl phthalate (DEHP). No safety issues of the plastic material were identified in USP biological tests in animals as well as by tissue culture toxicity studies.

ACTIONS

Dextrose and Sodium Chloride Injection USP solutions are a source of water for hydration and provide electrolytes and calories. Dextrose and Sodium Chloride Injection USP solutions are capable of inducing diuresis depending on the clinical conditions of the patient. See Table 1 for calories per liter of the various solutions.

Solutions which are di-electrolytic or polyelectrolytic have value in maintaining or replenishing electrolytes. See Table 1 for ionic concentrations.
INDICATIONS AND CLINICAL USE
Dextrose and Sodium Chloride Injection USP solutions are indicated as a supply of water or for administration of electrolytes or calories.

CONTRAINDICATIONS
Dextrose and Sodium Chloride Injection, USP is contraindicated in the following conditions:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the SUMMARY PRODUCT INFORMATION section of the Prescribing Information.
- Solutions containing dextrose should be used with caution in patients with known allergy to corn or corn products.
- Clinically significant hyperglycemia

WARNINGS AND PRECAUTIONS

General
Normal physiologic isotonicity range is approximately 280-310 mOsmol/liter. Administration of substantially hypotonic solutions may cause hemolysis and administration of substantially hypertonic solutions may cause vein damage.

Dextrose and Sodium Chloride Injection USP solutions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.

The intravenous administration of Dextrose and Sodium Chloride Injection USP solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the solutions.

Excessive administration of potassium free solutions may result in significant hypokalemia.

In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.

Hypersensitivity Reactions
Hypersensitivity/infusion reactions, including anaphylaxis, have been reported with Dextrose and Sodium Chloride Injection USP solutions (see ADVERSE REACTIONS).

Stop the infusion immediately if signs or symptoms of hypersensitivity/infusion reactions develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

Solutions containing dextrose should be used with caution in patients with known allergy to corn or corn products.

Hyponatremia
Use in patients at risk for sodium imbalance
Glucose intravenous infusions are usually isotonic solutions. In the body, however, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolism.

Monitoring of serum sodium is particularly important for hypotonic fluids. See Table 1 for information on the products’ osmolality. Depending on the tonicity of the solution, the volume and rate of infusion, and depending on a patient’s underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances, most importantly hypoosmotic or hyperosmotic hyponatremia.
High volume infusion must be used under specific monitoring in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including syndrome of inappropriate antidiuretic hormone secretion (SIADH), due to the risk of hospital-acquired hyponatremia.

Dextrose and Sodium Chloride Injection USP solutions should be used with particular caution, in patients with or at risk for hyponatremia is increased, for example,

- in children
- in elderly patients
- in women
- postoperatively
- in persons with psychogenic polydipsia
- in patients treated with medications that increase the risk of hyponatremia (See DRUG INTERACTIONS)

The risk for developing hyponatremic encephalopathy is increased (applies to solutions containing less than 0.9% sodium chloride), for example,

- in pediatric patients (≤16 years of age)
- in women (in particular, premenopausal women)
- in patients with hypoxemia
- in patients with underlying central nervous system disease.

Acute hyponatremia can lead to acute hyponatremic encephalopathy (brain edema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury.

Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

Use in patients at risk for sodium retention, fluid overload and edema

Dextrose and Sodium Chloride Injection USP solutions should be used with particular caution, in patients with or at risk for:

- Hypertremia (applies to solutions containing 0.9% sodium chloride)
- Hyperchloremia (applies to solutions containing 0.9% sodium chloride)
- Metabolic acidosis (applies to solutions containing 0.9% sodium chloride)
- Hypervolemia
- Conditions that may cause sodium retention, fluid overload and edema (central and peripheral), such as patients with
  - primary hyperaldosteronism,
  - secondary hyperaldosteronism associated with, for example,
    - hypertension,
    - congestive heart failure,
    - liver disease (including cirrhosis),
    - renal disease (including renal artery stenosis, nephrosclerosis)
  - pre-eclampsia.
- Medications that may increase the risk of sodium and fluid retention, such as corticosteroids.

Hypokalemia

The infusion of Dextrose and Sodium Chloride Injection USP solutions may result in hypokalemia.

Dextrose and Sodium Chloride Injection USP solutions should be used with particular caution in patients with or at risk for hypokalemia, close clinical monitoring may be warranted, for example:

- in persons with metabolic alkalosis
• in persons with thyrotoxic periodic paralysis, administration of intravenous dextrose has been associated in aggravating hypokalemia
• in persons with increased gastrointestinal losses (e.g. diarrhea, vomiting)
• prolonged low potassium diet
• in persons with primary hyperaldosteronism
• in patients treated with medications that increase the risk of hypokalemia (e.g. diuretics, beta-2 agonist, or insulin)

Risk of hypoosmolality and hyperosmolality, serum electrolytes and water imbalance

Depending on the volume and rate of infusion and depending on a patient’s underlying clinical condition and capability to metabolize dextrose, intravenous administration of Dextrose and Sodium Chloride Injection USP solutions can cause:

• Hyperosmolality, osmotic diuresis and dehydration
• Hypoosmolality (applies to solutions containing less than 0.9% sodium chloride)
  • Electrolyte disturbances such as
    - Hyponatremia, (see Hyponatremia and Use in patients at risk for sodium imbalance)
    - Hypokalemia,
    - Hypophosphatemia,
    - Hypomagnesemia,
• Overhydration/hypervolemia and, for example, congested states, including central (e.g. pulmonary congestion) and peripheral edema.
• Acid-base imbalance (applies to solutions containing 0.9% sodium chloride)
  • An increase in serum glucose concentration is associated with an increase in serum osmolality. Osmotic diuresis associated with hyperglycemia can result in or contribute to the development of dehydration and in electrolyte losses.

Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

Hyperglycemia

Rapid administration of dextrose solutions may produce substantial hyperglycemia and hyperosmolar syndrome.

In order to avoid hyperglycemia the infusion rate should not exceed the patient’s ability to utilize glucose.

To reduce the risk of hyperglycemia-associated complications, the infusion rate must be adjusted and/or insulin administered if blood glucose levels exceed levels considered acceptable for the individual patient.

Intravenous dextrose should be administered with caution in patients with, for example:
• impaired glucose tolerance (such as in diabetes mellitus, renal impairment, or in the presence of sepsis, trauma, or shock),
• severe malnutrition (risk of precipitating a refeeding syndrome),
• thiamine deficiency, e.g., in patients with chronic alcoholism (risk of severe lactic acidosis due to impaired oxidative metabolism of pyruvate),
• water and electrolyte disturbances that could be aggravated by increased glucose and/or free water load

Other groups of patients in whom Dextrose and Sodium Chloride Injection USP solutions should be used with caution include:
• patients with ischemic stroke. Hyperglycemia has been implicated in increasing cerebral ischemic brain damage and impairing recovery after acute ischemic strokes.
• patients with severe traumatic brain injury (in particular during the first 24 hours following the trauma). Early hyperglycemia has been associated with poor outcomes in patients with severe traumatic brain injury.

• Newborns (See Pediatric glycemia-related issues).

Prolonged intravenous administration of dextrose and associated hyperglycemia may result in decreased rates of glucose-stimulated insulin secretion.

Refeeding Syndrome

Refeeding severely undernourished patients may result in the refeeding syndrome that is characterized by the shift of potassium, phosphorus, and magnesium intracellularly as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. Careful monitoring and slowly increasing nutrient intakes while avoiding overfeeding can prevent these complications.

Use in Patients with or at risk of Severe Renal Impairment

Dextrose and Sodium Chloride Injection USP solutions should be administered with particular caution, to patients with or at risk of (severe) renal impairment. In such patients, administration of Dextrose and Sodium Chloride Injection USP solutions may result in sodium retention and/or fluid overload.

Blood

Dextrose and Sodium Chloride Injection USP solutions should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination (for solutions with Dextrose more or equal to 5%) or hemolysis.

Risk of Air Embolism

Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.

Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

SPECIAL POPULATIONS

Pregnancy and Lactation

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dextrose and Sodium Chloride Injection, USP is administered to a nursing mother.

Intrapartum maternal intravenous dextrose infusion may result in fetal hyperglycemia and metabolic acidosis as well as rebound neonatal hypoglycemia due to fetal insulin production.

Healthcare practitioners should carefully consider the potential risks and benefits for each specific patient before administering Dextrose and Sodium Chloride Injection, USP solutions.

Pediatrics

The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy. Plasma electrolyte
concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes.

The infusion of hypotonic fluids (applies to solutions containing less than 0.9% sodium chloride) together with the non-osmotic secretion of Antidiuretic hormone (ADH) may result in hyponatremia.

**Pediatric Glycemia-related Issues**

Newborns especially those born premature and with low birth weight - are at increased risk of developing hypo- or hyperglycemia. Close monitoring during treatment with intravenous dextrose solutions is needed to ensure adequate glycemic control, in order to avoid potential long term adverse effects.

Hypoglycemia in the newborn can cause, e.g.,
- prolonged seizures,
- coma, and
- cerebral injury, including brain damage.

Hyperglycemia has been associated with
- cerebral injury, including intraventricular hemorrhage,
- late onset bacterial and fungal infection,
- retinopathy of prematurity,
- necrotizing enterocolitis,
- increased oxygen requirements,
- prolonged length of hospital stay, and
- death.

**Pediatric Hyponatremia-related Issues**

Children (including neonates and older children) are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy.

The infusion of hypotonic fluids together with the non-osmotic secretion of ADH may result in hyponatremia (applies to solutions containing less than 0.9% sodium chloride).

Acute hyponatremia can lead to acute hyponatremic encephalopathy (brain edema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury.

Plasma electrolyte concentrations should be closely monitored in the pediatric population.

Rapid correction of hyponatremia is potentially dangerous (risk of serious neurologic complications). Dosage, rate, and duration of administration should be determined by a physician experienced in pediatric intravenous fluid therapy.

**Geriatrics**

When selecting the type of infusion solution and the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

**ADVERSE REACTIONS**

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

If any adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasure, and save the remainder of the fluid and administration set for examination if deemed necessary.
Other Adverse Reactions (Class Reactions)
Other adverse reactions reported with other similar products include:

- Hyponatremia, which may be symptomatic (applies to solutions containing 0.9% sodium chloride)
- Hyponatremic encephalopathy
- Acidosis Hyperchloremic (applies to solutions containing 0.9% sodium chloride)

Post-Marketing Adverse Reactions
The following adverse reactions have been reported in post-marketing experience:

**IMMUNE SYSTEM DISORDERS:** Anaphylactic reaction, Hypersensitivity

**METABOLISM AND NUTRITION DISORDERS:** Hyponatremia (applies to solutions containing less than 0.9% sodium chloride), Hypernatremia (applies to solutions containing 0.9% sodium chloride), Hyperglycemia

**VASCULAR DISORDERS:** Phlebitis

**SKIN AND SUBCUTANEOUS TISSUE DISORDERS:** Rash, Pruritus

**GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS:** Injection site reactions including: Infusion site pain, Injection site vesicles, chills, pyrexia

**DRUG INTERACTIONS**
Both the glycemic effects of Dextrose and Sodium Chloride Injection USP solutions and its effects on water and electrolyte balance should be taken into account when using Dextrose and Sodium Chloride Injection USP solutions in patients treated with other substances that affect glycemic control, or fluid and/or electrolyte balance.

Caution is advised in patients treated with lithium. Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection USP solutions and can result in decreased lithium levels.

Caution is advised when administering Dextrose and Sodium Chloride Injection USP solutions to patients treated with drugs leading to an increased vasopressin effect. The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and may increase the risk of hyponatremia following treatment with intravenous fluids. (See WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS).

- Drugs stimulating vasopressin release such as chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors (SSRIs), 3,4-methylenedioxy-N-methamphetamine, ifosfamide, antipsycotics, opioids.
- Drugs potentiating vasopressin action such as chlorpropamide, non steroid anti-inflammatory (NSAIDS), cyclophosphamide.
- Vasopressin analogues such as desmopressin, oxytocin, vasopressin, terlipressin.

Caution is advised when administering Dextrose and Sodium Chloride Injection USP to patients treated with drugs that may increase the risk of hyponatremia, such as diuretics and antiepileptics (e.g., oxcarbazepine).

Regarding medications that increase the risk of sodium and fluid retention, see WARNINGS AND PRECAUTIONS

**DOSAGE AND ADMINISTRATION**
As directed by a physician. The choice of the specific sodium chloride and dextrose concentrations, dosage, volume, rate and duration of administration depend on the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician. For patients with electrolyte and glucose abnormalities and for pediatric patients, consult a physician experienced in intravenous fluid therapy. All Dextrose and Sodium Chloride Injection USP solutions in VIAFLEX plastic containers are intended for intravenous infusion using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours.

Use of an in-line filter is recommended during administration of all parenteral solutions where possible.

Hyperosmolar solutions may cause venous irritation and phlebitis. Thus, any hyperosmolar solutions are recommended to be administered through a large central vein, for rapid dilution of the hypertonic solution. See Table 1 for information on the products’ osmolarity.
For solutions containing 10% Dextrose, the osmolarity of a final admixed solution must be taken into account when peripheral administration is considered.

Rapid correction of hyponatremia and hypernatremia is potentially dangerous (risk of serious neurologic complications). Dosage, rate, and duration of administration should be determined by a physician experienced in intravenous fluid therapy.

A gradual increase of flow rate should be considered when starting administration of dextrose-containing products.

Electrolyte supplementation may be indicated according to the clinical needs of the patient.

Additives may be incompatible. Compatibility of additives must be checked before adding medication. Those additives known or determined to be incompatible should not be used. When introducing additives to Dextrose and Sodium Chloride Injection USP solutions, the instructions for use of the medication to be added and other relevant literature must be consulted.

If in the informed judgment of the physician it is deemed advisable to introduce additives, use aseptic technique.

Before adding a substance or medication, verify that it is soluble in and/or stable in Dextrose and Sodium Chloride Injection USP solutions and that the pH range of Dextrose and Sodium Chloride Injection USP solutions is appropriate.

After addition, check for a possible color change and/or the appearance of precipitates, insoluble complexes or crystals.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless the solution is clear and the seal is intact.

Use of an in-line filter is recommended during administration of all parenteral solutions where possible.

Thorough and careful mixing of any additive is mandatory. Do not store solutions containing additives.

For single use only.

Discard any unused portion.

**OVERDOSAGE**

Excess administration of Dextrose and Sodium Chloride Injection USP solutions can cause:

- hyperglycemia, adverse effects on water and electrolyte balance, and corresponding complications. For example, severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal.
- hyponatremia (which can lead to CNS manifestations, including seizures, coma, cerebral edema and death).
- hypernatremia especially in patients with severe renal impairment (applies to solutions containing 0.9% sodium chloride).
- Fluid overload (which can lead to central and/or peripheral edema).
- See also **WARNINGS AND PRECAUTIONS** and **ADVERSE REACTIONS** sections

When assessing an overdose, any additives in the solution must also be considered.

Clinically significant overdose of Dextrose and Sodium Chloride Injection USP solutions may, therefore, constitute a medical emergency.

Interventions include discontinuation of Dextrose and Sodium Chloride Injection USP solutions administration, dose reduction, administration of insulin and other measures as indicated for the specific clinical constellation.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

**How Supplied**

Table 1 shows the composition, osmolarity, approximate pH, and ionic concentration of Dextrose and Sodium Chloride Injections.

Dextrose and Sodium Chloride Injection products are packaged in the Viaflex plastic container which is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic).
The available package sizes of Dextrose and Sodium Chloride Injection products are listed in Table 2.

Table 2. Package sizes of Dextrose and Sodium Chloride Injection products

<table>
<thead>
<tr>
<th>Product</th>
<th>Package size</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.3% Dextrose and 0.3% Sodium Chloride Injection</td>
<td>500mL, 1000mL</td>
</tr>
<tr>
<td>5% Dextrose and 0.2% Sodium Chloride Injection</td>
<td>500mL</td>
</tr>
<tr>
<td>5% Dextrose and 0.45% Sodium Chloride Injection</td>
<td>500mL, 1000mL</td>
</tr>
<tr>
<td>5% Dextrose and 0.9% Sodium Chloride Injection</td>
<td>500mL, 1000mL</td>
</tr>
<tr>
<td>10% Dextrose and 0.9% Sodium Chloride Injection</td>
<td>1000mL</td>
</tr>
</tbody>
</table>

Directions for use of VIAFLEX Plastic Container

WARNING: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air (approximately 15 mL) being drawn from the primary container before administration of the fluid from the secondary container is completed.

Do not remove unit from overwrap until ready to use.

To Open

Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. If supplemental medication is desired, follow directions below before preparing for administration. Some opacity of the plastic due to moisture absorption during sterilization process may be observed. This is normal and does not affect the solution quality and safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found discard solution as sterility may be impaired.

Preparation for Administration

1. Suspend container from eyelet support.
2. Remove plastic protector from outlet port at bottom of container.
3. Attach administration set. Refer to complete directions accompanying set.

To Add Medication

1. Prepare medication site.
2. Using a syringe and 20 - 22 gauge needle, puncture resealable rubber plug at target area and inject. Multiple additions may be made in this manner.
3. Mix solution and medication thoroughly. For high density medications such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

Storage

Store at 15°C to 25°C

Baxter Corporation

Mississauga, ON L5N 0C2

Baxter and VIAFLEX are trademarks of Baxter International Inc.

Last revised: December 14, 2018